Innovid Corp. Balance Sheet | Understand Stock

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated balance sheets

In millions of USD, except per-share amounts

	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021	Q2 FY2021 As of Jun 30, 2021	Q1 FY2021 As of Mar 31, 2021	Q4 FY2020 As of Dec 31, 2020
Assets
Current assets:
Cash and cash equivalents
Prepaid expenses
Deferred offering costs
Short-term bank deposits
Trade receivables, net of allowance for credit losses of $292 and $321 at September 30, 2024, and December 31, 2023, respectively
Prepaid expenses and other current assets
Due from Sponsor
Total current assets

Deferred offering costs
Cash and marketable securities held in Trust Account
Long-term restricted deposits
Long-term deposit
Long-term restricted deposits
Property and equipment, net
Goodwill
Intangible assets, net
Operating lease right of use asset
Other non-current assets
Total non-current assets
Total assets

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable and accrued expenses
Accrued offering costs
Promissory note — related party
Trade payables
Employee and payroll accruals
Current portion of long-term debt
Lease liabilities—current portion
Accrued expenses and other current liabilities
Promissory note - related party
Total current liabilities
Warrant Liabilities
Deferred underwriting fee payable

Warrant Liabilities
Deferred underwriting fee payable
Long-term debt
Lease liabilities—non-current portion
Other non-current liabilities
Warrants liability
Total non-current liabilities
TOTAL LIABILITIES
Class A ordinary shares, $0.0001 par value; 500,000,000 shares authorized; 25,300,000 and no shares subject to redemption at $10.00 per share as of September 30, 2021 and December 31, 2020, respectively
Preferred stocks - Authorized: 500,000 and 74,236,896 at December 31, 2021 and 2020, respectively; Issued and Outstanding: 0 and 73,690,340 at December 31, 2021 and 2020, respectively
Stockholders’ equity:
Common stock: $0.0001 par value - Authorized: 500,000,000 at September 30, 2024, and December 31, 2023; Issued and outstanding: 147,773,651 and 141,194,179 at September 30, 2024, and December 31, 2023, respectively
Class A ordinary Shares
Class B ordinary Shares
Total common stock: $0.0001 par value - Authorized: 500,000,000 at September 30, 2024, and December 31, 2023; Issued and outstanding: 147,773,651 and 141,194,179 at September 30, 2024, and December 31, 2023, respectively

Class B ordinary shares, $0.0001 par value; 50,000,000 shares authorized; 6,325,000 shares issued and outstanding as of June 30, 2021 and December 31, 2020
Treasury stocks, at cost (0 and 1,914,328 stocks at December 31, 2021 and 2020)
Additional paid-in capital
Accumulated deficit
Class B ordinary Shares
Total stockholders’ equity

Total liabilities and stockholders’ equity
Exchange ratio

Comments